A Phase 1 Safety and Pharmacokinetic Study of ABT-263 in Combination With Taxotere (Docetaxel) in the Treatment of Subjects With Solid Tumors.
Phase of Trial: Phase I
Latest Information Update: 26 Nov 2014
At a glance
- Drugs Navitoclax (Primary) ; Docetaxel
- Indications Solid tumours
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Abbott Laboratories
- 21 May 2012 Actual patient number changed from 50 to 41 as reported by ClinicalTrials.gov.
- 21 May 2012 Actual end date Mar 2012 added as reported by ClinicalTrials.gov.
- 21 May 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.